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T cell antigen receptor (TCR) triggering determines the fate of
immature thymocytes. The affinity of the TCR for its endogenous
peptideMHC ligands serves as a signal for positive or negative
selection through mechanisms that are still little understood. We
have used a conformation-specific antibody to demonstrate that
recognition of TCR ligands that lead to negative selection induces
a conformational change in the TCR in situ. In contrast, this
conformational change is elicited in only a small percentage of
immature thymocytes during positive selection. Using a TUNEL
assay, we demonstrate that the conformational change in the TCR
is strongly linked to activation of programmed cell death in
conditions leading to negative selection. Furthermore, the few
conformational change-positive thymocytes detected in condi-
tions that preferably lead to positive selection are also TUNEL-
positive. Thus, the conformational change in the TCR may underlie
the discrimination of ligands leading to positive and negative
selection.
signal transduction  thymic differentiation  negative selection
The T cell antigen receptor (TCR) complex is composed in mostT cells of the ligand-binding TCR and TCR subunits and the
signal-transducing CD3, CD3, CD3, and CD3 (CD247) (1, 2).
The differentiation of T cells is controlled by the transduction of
pre-TCR and TCR signals. Differentiation of immature
CD4CD8 double-positive (DP) to mature CD4 or CD8
single-positive thymocytes is initiated when the TCR- het-
erodimer engages the peptideMHC (pMHC) (2). A unique fea-
ture of the TCR is its ability to scan structurally similar pMHC
ligands and transmit distinct biochemical signals depending on the
strength of the ligand recognized (3, 4). In developing thymocytes,
weak TCR ligands induce positive selection, and stronger ligands
induce negative selection (5). However, mature T cells are tolerant
to weak TCR ligands in the periphery, and they respond to strong
ligands by activating a program of cell proliferation and cell
differentiation. The differential responsiveness of immature and
mature T cells to weak ligands constitutes the cornerstone of
self-tolerance that is acquired in the thymus.
Many studies have focused on how the TCR heterodimer
communicates ligand engagement to the CD3 subunits, how the
CD3 subunits translate this information into a specific cellular
response, and how the TCR complex discriminates between strong
and weak ligands. The engagement of the TCR with a weak ligand
in mature T cells results in a distinct pattern of intracellular
signaling compared with that induced by a full-agonist peptide. For
example, stimulation with a weak ligand induces only partial
phosphorylation of the CD3 and CD3 chains and the recruit-
ment, but not the phosphorylation, of the -associated protein of 70
kDa, ZAP70 (6, 7). Hence, weak ligands activate only a subset of
the downstream signaling pathways that are activated by an agonist
peptide (8). Weak ligands bind to the TCR with a lower affinity and
a higher dissociation rate than full agonists (9). These kinetic
parameters are consistent with a model in which shorter occupancy
of the TCR may provoke partial signaling. However, in addition to
their different kinetics, occupancy of the TCR by weak ligands may
produce structural rearrangement of the TCR that differs from that
produced by nominal peptide ligands.
Whereas a conformational change in the TCR may be the earliest
event that occurs upon TCR engagement (10), crystallographic
analysis of complexes formed by the ectodomains of pMHC and
TCR reveal ligand-induced conformational changes only in the
complementarity-determining regions (CDR) of the TCR-variable
domains (11–13). However, these structural changes were thought
to accommodate pMHC binding and, with one exception (14), are
not accompanied by a corresponding conformational change in the
constant domains of the TCR. Furthermore, the changes in the
conformation of the CDR when TCRs bound variant pMHC
ligands were only minor when compared with those provoked by
nominal peptide antigens (11, 13). These crystallographic studies
argue that conformational changes in the CDR loops may not be
communicated to the distal domains of the TCR–CD3 complex.
Using a biochemical approach, we found that the TCR undergoes
a conformational change in mature T cells when engaged by a
strong, but not by a weak, stimulatory mAb (10). This conforma-
tional change uncovered a cryptic epitope in the cytoplasmic tail of
CD3, revealing a polyproline sequence that serves as a binding site
for the SH3.1 domain of the cytosolic adapter protein, Nck. Using
this biochemical approach, a pull-down assay with GST fused to the
SH3.1 domain, we recently showed that this conformational change
is induced by positive- and negative-selecting pMHC ligands in vitro
and that MHC is required (15). However, this biochemical assay is
limited, because it does not discriminate between thymocyte subsets
or identify which individual cells are responding to the different
stimuli. Most importantly, the biochemical assay does not deter-
mine whether the conformational change is really taking place in
vivo. However, we identified a mAb that recognizes the polyproline
sequence in CD3 (mAb APA11) and that can be used to detect
the conformational change in peripheral lymphoid tissues both in
vitro and in vivo (16). Here, we have used APA11 to characterize
the spatial distribution of thymocytes undergoing the conforma-
tional change in the TCR during differentiation. We have examined
their phenotype, the proximity of the cells to the pMHC ligand-
presenting stromal cells, and their frequency in the context of
positive and negative selection. Our results show that only a few, or
none, of the TCRs of DP thymocytes undergo a conformational
change in vivo to pMHC ligands when eliciting positive selection,
but many do so in the presence of negative-selecting pMHC,
suggesting that the conformational change in the TCR is elicited by
strong stimuli in the thymus and could help to activate the negative-
selection program.
Results
The TCR of only a Small Percentage of DP Thymocytes Is Undergoing
a Conformational Change in Vivo. In contrast to the GST-Nck
pull-down assay, immunostaining with mAb APA11 identifies the
cells in which the TCR undergoes a conformational change upon
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engagement in situ. Immunohistochemistry on sections of the
thymus of C57BL6 mice revealed that most thymocytes were
stained with the conventional anti-CD3 antibody 500A2, but only
a few were stained with APA11 (Fig. 1A). APA11 staining was
not distributed uniformly in the labeled thymocytes, but was, rather,
concentrated in a region of the plasma membrane in which the TCR
accumulates (Fig. 1B, arrows). However, we did frequently observe
an accumulation of the TCR at one pole of the thymocyte without
the concomitant exposure of the APA11 epitope (Fig. 1B, arrow-
heads). This pattern of staining offers evidence that APA11
staining is not simply a direct translation of TCR clustering.
Furthermore, the specificity of the APA11 antibody was demon-
strated by the absence of staining when thymus sections were
incubated in the presence of an excess of GST protein fused to the
cytoplasmic tail of CD3 (GST), which contains the APA11
epitope (Fig. 1A). In similar conditions, APA11 staining was
unaffected, as was the staining with the anti-CD3 500A2 in the
presence of GST alone. These results indicate that the APA11
antibody specifically recognizes the polyproline epitope of the TCR
in tissue sections of the thymus.
To study the distribution of thymocytes in which the TCR has
undergone a conformational change, sections were labeled with
both APA11 and either a pancytokeratin antibody as a marker for
the thymus cortex or anti-CD5 as a marker of the medulla (17). The
majority of APA11-positive cells were concentrated in either the
cortex or at the corticomedullar junction (99%; Fig. 1C and data
not shown). The medulla itself remained practically devoid of
APA11 staining. In agreement with this cortical distribution,
virtually all cells recognized by APA11 also expressed CD4 and
CD8 (99%, Fig. 1D; and see Table 1, which is published as
supporting information on the PNAS web site, for details on
quantitation). Only a few APA11-labeled cells were situated in the
subcapsular area, and these were not recognized by antibodies
against CD4 and CD8 (data not shown), suggesting that the
APA11 epitope might be exposed at some point during the pre-T
cell stage. These results indicate that most thymocytes in which the
TCR polyproline epitope is exposed correspond to a small popu-
lation of thymocytes that express CD4 and CD8 in the cortex and
at the corticomedullar junction.
The TCR Undergoes a Conformational Change Under Conditions Lead-
ing to Negative Selection. We previously demonstrated that expo-
sure of the APA11 epitope in peripheral mature T cells occurred
in response to strong, but not to weak, ligands (16). Because, in
developing thymocytes, weak TCR ligands induce positive selection
and stronger ligands induce negative selection (5), we next aimed to
determine whether exposure of the APA11 epitope correlated
with negative selection. To this end, we took advantage of the HY
TCR transgenic mouse model. HY TCR-expressing thymocytes are
positively selected in females with the H2-Db background, whereas
these thymocytes are negatively selected in males of the same
background (18). We detected a slight increase in the number of
thymocytes recognized by APA11 in females with a selecting
background (bd) compared with females with nonselecting back-
ground (dd, Fig. 2 A and C). In males, the difference was much
more striking, and there was a 20-fold increase in the number of
thymocytes labeled by APA11 in the negative-selecting (bd) vs.
the nonselecting (dd) background. As in nontransgenic mice (Fig.
1D), most APA11-positive thymocytes in male HY TCR trans-
genics were DP (see Fig. 5, which is published as supporting
information on the PNAS web site). Indeed, up to 50% of the DP
thymocytes were recognized by APA11 in the bd background
(Fig. 2 B and C). These results indicate that the conformational
change in the TCR could contribute to activation of the negative-
selection program.
In both female and male HY TCR transgenics, most thymo-
cytes exposing the APA11 epitope were in close contact with
epithelial and thymic dendritic cells (Fig. 2 A and B). Further-
Fig. 1. Binding to the APA11 epitope in the nontransgenic murine thymus.
(A) APA11 is available in a small number of CD3 thymocytes. Thymus
sections (10 m) from 6-week-old C57BL6 mice were simultaneously stained
with 500A2-Alexa Fluor 488 (anti-CD3) and APA11 antibodies, without com-
peting protein, or in the presence of either 4 gml GST or GST. The
secondary antibody used was anti-mouse Ig Alexa Fluor 594 (red). (Scale bars,
20 m.) APA11 labeling of thymocytes is indicated by arrowheads. (B) The
APA11 epitope is distributed in a polarized manner in thymocytes. Thymus
slices were double-stained as in Awith a conventional anti-CD3 antibody and
APA11. The arrows point to regions in the cells where the APA11 epitope is
concentrated, whereas the arrowheads show concentrations of CD3 where
APA11 does not bind. (Scale bars, 5 m.) (C) APA11 antibody binds to the
TCR in the cortex of the thymus but not in the medulla. Thymus sections from
C57BL6 mice were stained as in A but with a pancytokeratin antibody as a
marker for the cortex and an anti-CD5 antibody as a marker for the medulla.
(D) APA11 binds to CD4CD8 thymocytes. Thymus sections were triple-
stained with APA11 and with antibodies against CD4 and CD8. Arrows
indicate the presence of APA11-labeled cells. (Scale bars, 5 m.) In A–C, the
single-coloredmicrographs are shown ingrayscale topresent awider rangeof
staining.
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more, the APA11 staining was polarized toward the antigen-
presenting cell (APC). These results were also obtained in
nontransgenic mice (data not shown) and suggest that the
conformational change in the TCR takes place in thymocytes
that contact APCs in the thymus and that the conformational
change occurs only at immune synapses.
The HY TCR is MHC class I-restricted, and its cognate antigen
is constitutively expressed in male mice. In this model, it is therefore
not possible to time the expression of a strong TCR ligand and
induction of the conformational change. To study the induction of
the conformational change in a class II-restricted TCR and, most
important, to do a timely study of both induction of the confor-
mational change and negative selection, we analyzed APA11
binding in AND TCR transgenic mice that express an agonist
peptide under control of a tetracycline-responsive promoter (19). In
brief, these mice express a MHC class II-driven transactivator (TA)
that is negatively regulated by tetracycline (Tet-off) and which
directs the expression of the strong agonist MCCp embedded in the
invariant chain (TIM). In the absence of tetracycline, the TIM-
encoded MCCp can be presented by endogenous I-Ek and pro-
motes the deletion of thymocytes bearing the AND TCR (Fig. 3A).
However, when tetracycline is administered for 8–10 days, the
distribution of thymic populations and the size of the thymus is
similar to that of control AND TCR transgenic mice, wherein most
thymocytes are being positively selected. If tetracycline adminis-
tration is interrupted, TIM is reexpressed, and the DP population
gradually disappears over the next 48 h (Fig. 3A). The expression
of the negatively selecting TIM construct induced by the removal of
tetracycline was verified by real-time PCR (Fig. 3B). To study the
exposure of the APA11 epitope during positive and negative
selection, tetracycline was given to RAG1-deficient AND-TA-TIM
mice for 10 days and then removed for different time periods (Fig.
3C). In this way, more or less synchronized populations of thymo-
cytes undergoing positive and negative selection should be gener-
ated. Thymus sections were stained with APA11 and anti-CD8
antibodies to evaluate the conformational change within the DP
population. As a general marker for cell activation, thymus sections
were stained with the anti-phosphotyrosine antibody 4G10. Re-
moval of tetracycline and the concomitant expression of TIM (Fig.
3B) resulted in an increase in the number of CD8 cells (predom-
inantly DP thymocytes) recognized by APA11 (Fig. 3C). However,
total tyrosine phosphorylation did not change upon tetracycline
removal, suggesting that the negative-selecting ligand specifically
induced the conformational change in the TCR and that this was
not a result of generally increased signaling by the TCR. This effect
was most clearly seen when APA11 binding was quantified in the
DP cell population. When compared with nontransgenic mice, the
expression of the anti-phosphotyrosine marker increased 4-fold in
thymuses of AND transgenic and 7-fold in AND-TA-TIM mice
maintained on tetracycline for 10 days. Nevertheless, the total
tyrosine phosphorylation did not increase upon removal of tetra-
cycline and expression of the TIM negative-selecting ligand (Fig.
3C). However, removal of tetracycline did cause an increase (24-
fold) in APA11 labeling 48 h later. Furthermore, maximal TIM
expression (Fig. 3B) correlated with maximal deletion of DP
thymocytes (Fig. 3A) and maximal expression of APA11 (Fig. 3C).
These results expand those obtained in the HY TCR transgenic
system and suggest that the conformational change in the TCR is
promoted by ligands that lead to negative, but not to positive,
selection.
The Conformational Change in the TCR Is Strongly Linked to Thymo-
cytes That Are Being Negatively Selected.Up to this point, our results
suggested a correlation between induction of the conformational
change in the TCR and negative selection, because both processes
are induced by strong TCR ligands. However, a direct linkage
between the two events was missing. We therefore performed a
double-staining of thymus sections of AND-TA-TIM mice under
conditions of positive and negative selection (Fig. 3A) in search for
APA11-positive and TUNEL-positive (apoptotic) cells. We found
an association between the two markers in conditions that prefer-
ably lead to positive selection (10 days of tetracycline treatment)
and in conditions that lead to negative selection (48 h after
tetracycline removal) (Fig. 4A, arrows). Quantitation of the number
of TUNEL-positive cells revealed a 13-fold increase in conditions
leading to negative selection vs. conditions leading to positive
selection (Fig. 4B), suggesting that expression of the TIM negative-
selecting ligand (Fig. 3B) leads to increased apoptosis. The analysis
of TUNEL-positive cells revealed a striking association with the
APA11-positive population, in comparison with the general CD3-
positive population (Fig. 4C, after 48-h tetracycline removal). The
association between TUNEL and APA11 staining was not, how-
ever, maintained when dexamethasone, a TCR-independent apo-
Fig. 2. The APA11 antibody is bound more strongly during negative
selection, but not during positive selection, in HY TCR transgenic mice. (A)
Thymus sections of female HY TCR transgenic mice on a positive-selecting
background (bd) or not (dd). APA11-stained sections were counterstained
with the pancytokeratin marker that labels the area where most thymocytes
recognized by APA11 concentrate. (B) Thymus sections of male HY TCR
transgenic mice that do or do not express the negatively selecting b back-
ground. Sectionswere counterstainedwith anti-CD11c,which labels the areas
richest in thymocytes recognized by APA11. (C) Quantification of APA11
binding as a percentage of the APA11-labeled cells with respect to the total
number of cells (quantified after ToPro staining). Values represent the mean
and standard deviation of data generated in sextuplicate (three mice per
experimental point, two fields per sample). In A and B, the single-colored
micrographs are shown in grayscale to present a wider range of staining.
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ptotic stimulus, was used (see Fig. 6, which is published as support-
ing information on the PNAS web site). These results indicated that
exposure of the APA11 epitope was not a consequence of
apoptosis and, together with those of Fig. 4, suggest that induction
of the conformational change in the TCR is linked to the induction
of programmed cell death. Most interesting, the analysis of thy-
muses in which DP thymocytes preferably undergo positive selec-
tion show that 82% of the APA11-positive thymocytes are
TUNEL-positive, whereas only 3% of the CD3-positive cells are
TUNEL-positive (Fig. 4C, 10 days of tetracycline treatment). This
result suggests that the small percentage of thymocytes exposing the
APA11 epitope in conditions that preferably lead to positive
selection are indeed undergoing negative selection. The association
of APA11 staining with apoptosis is not due to an aberrant
exposure of the CD3 epitope The association of APA11 staining
with apoptosis, therefore, establishes a direct link between the
conformational change in the TCR and negative selection.
Discussion
In this study, we show that the APA11 epitope is displayed in the
TCR of only a minority of thymocytes in nontransgenic mice. This
result suggests that the TCR in only a fraction of the total thymic
population undergoes the conformational rearrangement at any
given time. The use of cortical and medullar markers as well as the
use of anti-CD4 and anti-CD8 antibodies enabled us to define the
population of thymic cells recognized by APA11. These cells were
predominantly DP thymocytes that are present in the cortex and the
corticomedullar junction, in close contact with epithelial and den-
dritic cells. The phenotype and the location of the APA11-labeled
thymocytes strongly suggest that the conformational change in the
TCR is linked to the processes of positive andor negative selection.
We have recently shown, using the GST-Nck pull-down assay, that
both positive- and negative-selecting pMHC ligands induce the
conformational change in the TCR in vitro (15). These results
indicate that this conformational change distinguishes between null
Fig. 3. The APA11 epitope is strongly exposed in conditions leading to negative selection in AND TCR DP thymocytes. (A) Flow-cytometry analysis of thymic
populations from AND TCR transgenic mice with or without the TA (tet-off) and TIM constructs. AND-TA-TIM triple-transgenic mice were given tetracycline in
their drinking water for 10 days to repress the expression of the negative-selecting TIM construct (predominant positive-selection conditions). After the
tetracycline treatment (10 days), some of the mice were deprived of tetracycline for the number of hours indicated to allow reexpression of the TIM construct.
One lobule of each thymuswas used for flow cytometry and PCR analysis and the other for immunohistochemistry (see C below) The percentage of DP and CD4
SP thymocytes produced by each regime is indicated. (B) Expression of TIM mRNA measured by real-time PCR. (C) Sections from the intact lobules of the mice
analyzed in A and B were triple-stained with APA11 and with antibodies for CD8 and anti-phosphotyrosine (4G10). The merged image shows the staining of
APA11 within the CD8 population. The single-colored micrographs are shown in grayscale to present a wider range of staining. (D) Quantification of APA11
binding and phosphotyrosine expression. As shown in C, sections were triple-stained with anti-CD4, anti-CD8, and APA11 to estimate the percentage of
thymocyteswithin theDP population stained byAPA11. Values are represented as bars and indicate themean and standard deviation of data taken in triplicate
(one mouse per experimental point, three fields per point). The 4G10 expression was measured as total fluorescence intensity by using the IMAGEJ program and
expressed in arbitrary units.
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and signaling pMHCs but not between pMHC ligands inducing
positive and negative selection. Accordingly, the conformational
change in the TCR would not predict the TCR signal strength.
Although these data appear to contradict the results obtained with
the APA11 antibody in mature T cells (16), they could be
explained by the observation that the TCR on thymocytes is much
more sensitive to pMHC as compared with the TCR of mature T
cells (20). The APA11 antibody recognizes the proline-rich se-
quence in the tails of human and murine CD3 (ref. 21 and data not
shown) only after engagement of the TCR (16). We showed that the
epitope recognized by APA11 is displayed only in immunological
synapses when the antigen-presenting cell is loaded with a full, but
not a partial, agonist. Because partial agonists promote positive
selection in the thymus and full agonists promote negative selection,
it was important to determine whether the conformational change
in the TCR of thymocytes was correlated with signal strength, as in
mature T cells. The association of the conformational change with
negative selection was apparent in the HY TCR transgenic model
and in an AND TCR triple-transgenic mouse line that expresses the
strong MCCp agonist regulated by a tetracycline-responsive pro-
moter. In both class I-restricted (HY) and class II-restricted (AND)
TCR transgenic models, we observed a correlation between the
expression of the strong negative-selecting agonists and the con-
formational change in the TCR. The TUNEL and APA11 staining
does, however, show a direct relation between induction of the
conformational change and negative selection in thymuses of AND
TCR triple-transgenic mice (Fig. 4). Most interesting, the few
APA11-positive thymocytes detected in conditions that preferably
lead to positive selection are TUNEL-positive, suggesting that these
thymocytes are also being negatively selected. Because the AND
TCR triple-transgenic mice are in a RAG1-deficient background,
all DP thymocytes should bear the AND TCR and could be
expected to be positively selected in the absence of the strong
MCCp agonist. It is, nevertheless, possible that some leaky expres-
sion of MCCp, even in the presence of tetracycline or the natural
negatively selecting ligands in the thymus, account for the finding
of APA11 and TUNEL double-positive cells. Moreover, the
existence of some degree of negative selection in AND TCR
transgenic mice has been suggested (22, 23).
It has been shown that positively selecting ligands induce a low
but sustained activation of extracellular signal-regulated kinase
(ERK), whereas negatively selecting ligands induce a robust but
brief peak of ERK activity (20, 24). More recently, it has been
shown that inhibition of ERK activity, even 24 h after exposure to
a positively selecting ligand, blocks maturation of CD8 single-
positive thymocytes (25), suggesting that a sustained ERK activa-
tion is required for positive selection. Because induction of the
conformational change in the TCR is a very early event (10, 16), it
was not expected that expression of the conformational change
marker (APA11) was coincident with expression of a marker for
a late event such as apoptosis. The strong linkage between expres-
sion of the APA11 epitope and TUNEL-positive cells suggests
that the TCR undergoes a sustained conformational change in
conditions leading to negative selection.
Unlike our earlier study based on the pull-down assay (15), the
APA11 immunohistochemical data from mature T cells (16) and
thymocytes (this study) suggests that the conformational change in
the TCR reflects the engagement of strong agonists. The lower rate
of dissociation from the TCR is a characteristic that distinguishes
strong agonists from weak agonists. According to our results, the
kinetic parameters of the TCR–pMHC interaction could be directly
translated by the TCR into a conformational change. Thus, the
short occupancy of the TCR is correlated with a lower probability
of the CD3 tails undergoing a conformational change, whereas
occupancy for a longer period results in a sustained rearrangement
of the CD3 tails. Therefore, the conformational change in the TCR
would be a direct result of sustained agonist binding. A long
exposure of the polyproline epitope could be responsible for the
activation of a specific set of signaling cascades that might lead to
full activation in mature T cells or to apoptosis in DP thymocytes.
However, it is still unclear what signaling cascades may be activated
as a direct consequence of the exposure of this epitope. So far, the
conformational change has been described only for the cytoplasmic
tail of CD3. However, it seems likely that the tails of other CD3
subunits will also be rearranged upon activation (26), although this
result remains to be demonstrated in vivo. If the conformational
change influences the tyrosine phosphorylation of the CD3 immu-
noreceptor tyrosine-based activation motifs, it could constitute an
additional mechanism to transduce the strength of interaction with
pMHC ligands into different T cell responses. Nevertheless, the
only change so far demonstrated is the exposure of the proline-rich
sequence in CD3. We have identified the association of Nck with
this sequence, showing that it binds to CD3 through its N-terminal
SH3.1 domain (10). Whether Nck recruitment to the proline-rich
Fig. 4. Most APA11 epitope-expressing cells are already engaged in pro-
grammed cell death. (A) Sections from the intact lobules of AND-TA-TIM
triple-transgenic mice shown in Fig. 3 were triple-stained with either APA11
or anti-CD3 antibody 500 A2 (green), for TUNEL (red), and with ToPro as a
nuclei marker (blue). Themerged image is shown and illustrates the presence
of TUNEL and APA11 DP thymocytes (arrows) and the presence of TUNEL-
positive but APA11-negative thymocytes (arrowheads). (Scale bars, 20 m.)
(B) Quantification of TUNEL-positive cells. The number of TUNEL-positive cells
was counted from micrographs of sections as shown in A and referred to the
total number of cells, estimated according to the staining with the nuclei
marker ToPro. Three optical fields per mouse were counted with a number of
20–30 TUNEL-positive cells per field for the mouse treated with tetracycline
for 10 days, and with a number of 100–200 TUNEL-positive cells per field for
themouse treatedwith tetracycline for 10 days and subsequently deprived of
tetracycline for 48 h. (C) Quantification of the TUNEL-positive cells within the
APA11-positive population andwithin the general CD3-positive population.
ThepercentageofTUNEL-positive thymocyteswithin theAPA11-positiveand
CD3-positive populations was estimated as in B.
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sequence of CD3 is directly responsible for ‘‘sensing’’ the quality
of the ligand and for promoting negative selection remains un-
known.
The importance of the CD3 proline-rich sequence in thymic
development has recently been brought into question (27). Bone
marrow chimeras in CD3-deficient mice have been used to express
a CD3mutated in the proline-rich sequence before studying T cell
development. No gross abnormalities were observed in the distri-
bution of thymic populations, in accordance with our observation
that the conformational change is not elicited during positive
selection. Unfortunately this system does not offer information
regarding the role of the CD3 proline-rich sequence in negative
selection because it was not studied in transgenic TCR models (27).
Therefore, we propose that the direct recruitment of Nck to the
TCR is necessary to activate the negative-selection program. In-
deed, misshapen-Nck-interacting (NIK)-related kinase (MINK) is
a serine–threonine kinase that binds to Nck (28) and that has been
shown to selectively connect the TCR to a signaling pathway leading
to negative but not positive selection (29). The results shown in this
study linking the conformational change in the TCR with negative
selection are in keeping with the proposed role for MINK (29), and
they suggest that association of Nck-MINK with the TCR during
negative selection depends on a conformational change in the TCR
complex.
Methods
Cells and Mice. TCR transgenic mice bearing a TCR responsive to
the male HY antigen presented by H-2Db (HY) or a TCR respon-
sive to MCCp presented by I-Ek (AND) have been described (30,
31). The AND-TA-TIM triple-transgenic mice express the AND
TCR together with a TIM construct containing the I-Ek-restricted
MCC epitope under regulation of a tetracycline-responsive pro-
moter (Tet-off) (19). These mice were bred onto a RAG1-deficient
H-2k-positive background. All mice were bred and maintained free
of pathogens at our animal facility.
Antibodies and Other Reagents. The anti-CD3 mouse mAb
APA11 has been described (32) and is commercially available
from Upstate Biotechnology (Lake Placid, NY). Hamster anti-
mouse CD3 Alexa Fluor 488 (clone 500A2), rat anti-mouse CD8
Alexa Fluor 488 (clone 5H10), and rat anti-mouse CD4 Alexa Fluor
647 (clone RM4–5) mAbs were all purchased from Caltag (South
San Francisco, CA). The biotin anti-mouse CD5 was from BD
Pharmingen, hamster anti-mouse CD3 145–2C11 hybridoma was
obtained from the American Type Culture Collection, the FITC-
labeled monoclonal anti-pancytokeratin (clone C11) was from
Sigma, and the anti-phosphotyrosine (4G10) was from Upstate
Biotechnology. Hamster anti-murine CD11c mAb N418 was a gift
from C. Ardavı´n (Centro Nacional de Biotecnologı´a).
Immunohistochemical Studies. Thymuses were fixed with 4% para-
formaldehyde in PBS, washed with PBS, and incubated overnight
in a 30% sucrose solution in PBS at 4°C. The thymuses were
embedded in optimal cutting temperature compound (Tissue-Tec;
Miles Scientific, Naperville, IL), and, subsequently, 10-m cryostat
sections were obtained by using a 2800 Frigocut N cryostat (Leica).
The sections were fixed again with 4% paraformaldehyde in PBS,
quenched with 20 mM NH4Cl, and stained for 1 h with antibodies
in a solution containing 5% FBS. The secondary antibodies used
were goat anti-mouse Alexa Fluor 488, Alexa Fluor 594 or Alexa
Fluor 647 (Caltag), and the sections were finally mounted in
fluorescent mounting medium (DAKO). The samples were visu-
alized on a confocal LSM510 Meta laser scanning microscope
(Zeiss) at40 magnification, with the pinhole adjusted to a 1.5-m
section. Detectors were set to obtain the optimal signals below
saturation. All samples that are compared in a figure were prepared
simultaneously, and the visualization and acquisition of the images
were also performed the same day, with the same settings. Images
were analyzed with the LSM 5 Image Browser and IMAGEJ soft-
ware. Quantitation was done by a code-blind observer.
TUNEL Assay. Apoptotic cell death was determined in 10-m-thick
cryostat sections of murine thymuses by using TUNEL staining
according to the manufacturer’s instructions (Roche). dUTP la-
beling of DNA strand breaks was visualized on a confocal LSM519
Meta microscope.
Quantitative PCR. Expression of the TIM construct was measured
by real-time PCR as described (19).
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